# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Zelda Fitzgerald (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET004-SYN-TD
- Date: 1930-05-11
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margot Ellery, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for establishing primary care twelve days after discharge from a first psychiatric admission: provisional diagnosis and differential, antipsychotic monitoring baseline, missed periods, eating and exercise, and safety planning. **S**

## Objective

White cells: 6.1 10*3/uL; Hemoglobin: 12.6 g/dL; Platelets: 248 10*3/uL; Sodium: 139 mmol/L; Potassium: 4 mmol/L; Creatinine: 0.72 mg/dL; eGFR: 116 mL/min/1.73 m²; Glucose: 84 mg/dL; Calcium: 9.4 mg/dL; TSH: 2.1 mIU/L; Prolactin: 62 ng/mL (high); Hemoglobin A1c: 5%; Total cholesterol: 168 mg/dL; LDL cholesterol: 90 mg/dL; HDL cholesterol: 64 mg/dL; Triglycerides: 70 mg/dL; PHQ-9: 11; AUDIT-C: 2. All results are synthetic.

BP 108/68 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 50.8 kg; BMI 18.7 kg/m². All vital signs are synthetic.

## Assessment

Active problems: First episode of psychosis with marked mood symptoms: about three weeks of little sleep, rapid speech, racing thoughts, grandiose plans and very long training days, then a voice commenting on her dancing and a belief that she was being watched and tested; tearful low mood since discharge. Diagnosis provisional; differential: bipolar I disorder with psychotic features, schizoaffective disorder (bipolar type), and schizophreniform disorder or schizophrenia, depending on whether the psychosis ever occurred apart from the mood symptoms. Synthetic modern episode linked to her documented first hospitalization; Secondary amenorrhea: no periods for about four months before admission, during very heavy dance training at a low weight (BMI 18.7), with prolactin raised on risperidone; pregnancy test negative. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Continued without change: Risperidone 2 mg oral tablet, one tablet by mouth at bedtime (started in hospital) **S**

## Plan

- Continue the antipsychotic started in hospital, with monitoring to the APA and ADA/APA standard: weight at every visit, blood pressure, fasting glucose or A1c and lipids at baseline, 12 weeks and yearly, prolactin because her periods have stopped, side-effect checks, and the AIMS at baseline and every six months. Guideline: The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020); Consensus development conference on antipsychotic drugs and obesity and diabetes (2004); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
- Psychiatry consultation with the first-episode psychosis coordinated specialty care team on the provisional diagnosis and how to settle it, a mood stabilizer to prevent another episode, and the antipsychotic choice given her raised prolactin and missed periods. Guideline: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018); The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020); Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026) **S**
- Reproductive health on psychiatric medicines: a pregnancy test before any new medicine, valproate avoided because of its risks in pregnancy, counseling on the risks of any mood stabilizer in pregnancy, contraception that suits her, folic acid, and planning with psychiatry before any pregnancy. Guideline: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018); U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024) **S**
- Eating and exercise: the SCOFF screen, menstrual and energy review at each visit, a sports dietitian, and a graded return to dance with food matched to the training load; training hours watched as an early warning sign. Guideline: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018); The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020) **S**
- Coordinated specialty care: a care coordinator, individual therapy with psychoeducation about mood and psychosis, education for the people she chooses, support to return to dance and writing, and a peer specialist. Guideline: The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020); Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026) **S**
- Sleep and early warning signs: regular sleep and wake times, no all-night writing or training, and a plan to call the team after two short nights or if training hours climb. Guideline: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018) **S**
- Structured safety assessment, a written safety plan with early warning signs, lethal-means counseling, the 988 Suicide & Crisis Lifeline, the PHQ-9 at each visit, and safety review at every visit. Guideline: Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
